NasdaqGS:STTK 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	3	-85	19
31 Dec 23	2	-87	19
30 Sep 23	1	-95	20
30 Jun 23	1	-92	21
31 Mar 23	1	-98	20
31 Dec 22	1	-102	20
30 Sep 22	30	-69	21
30 Jun 22	32	-61	19
31 Mar 22	28	-58	19
31 Dec 21	30	-45	19
30 Sep 21	1	-65	18
30 Jun 21	2	-59	16
31 Mar 21	9	-42	12
31 Dec 20	10	-37	9
30 Sep 20	11	-32	7
30 Jun 20	11	-27	6
31 Mar 20	10	-26	6
31 Dec 19	10	-24	6
31 Dec 18	22	-7	4

양질의 수익: STTK 은(는) 현재 수익성이 없습니다.

이익 마진 증가: STTK 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: STTK 은(는) 수익성이 없으며 지난 5년 동안 연간 30.5% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 STTK 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: STTK 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: STTK 현재 수익성이 없기 때문에 마이너스 자본 수익률( -66.05% )을 갖습니다.

Shattuck Labs 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Recent updates

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

Price target decreased by 7.9% to US$14.50

Shattuck Labs, Inc. Announces Committee Appointments

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 159%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Chief Financial Officer exercised options to buy US$250k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020)

High number of new and inexperienced directors

General Counsel notifies of intention to sell stock

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$2.31m

General Counsel notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Shattuck Labs names Abhinav Shukla as chief technical officer

Co-Founder & Chairman of the Board notifies of intention to sell stock

Co-Founder & Chairman of the Board notifies of intention to sell stock